Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study-Reference-Cited by-同舟云学术

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Published:2015-07-22 Issue:3 Volume:171 Page:373-377
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Voorhees Peter M.¹,Orlowski Robert Z.²,Mulkey Flora³,Watson Peter⁴,Geyer Susan⁵,Sanford Ben L.³,Bennett Elizabeth³,Chanan-Khan Asher A.⁶,Bloomfield Clara D.⁷,Larson Richard A.⁸

Affiliation:

1. Division of Hematology-Oncology; the University of North Carolina Lineberger Comprehensive Cancer Center; Chapel Hill NC USA

2. Department of Lymphoma/Myeloma; the University of Texas MD Anderson Cancer Center; Houston TX USA

3. Alliance Statistics and Data Center; Duke University Medical Center; Durham NC USA

4. Department of Oncology; Kinston Medical Specialists, P.A.; Kinston NC USA

5. Health Informatics Institute; University of South Florida; Tampa FL USA

6. Department of Hematology/Oncology; Mayo Clinic; Jacksonville FL USA

7. Division of Hematology; The Ohio State University Comprehensive Cancer Center; Columbus OH USA

8. Department of Medicine; University of Chicago Comprehensive Cancer Center; Chicago IL USA

Funder

National Cancer Institute of the National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13592/fullpdf

Reference14 articles.

1. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project;Avet-Loiseau;Leukemia,2013

2. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for blood and marrow transplant;Blade;British Journal of Haematology,1998

3. Regression models and life-tables;Cox;Journal of the Royal Statistical Society. Series B (Methodological),1972

4. A proportional hazards model for the sub-distribution of a competing risk;Fine;Journal of American Statistical Association,1999

5. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma;Jakubowiak;Journal of Clinical Oncology,2009

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety;Frontiers in Oncology;2021-03-25

2. Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma;Frontiers in Genetics;2019-09-18

3. Passive Targeting of Nanoparticles to Cancer;Surface Modification of Nanoparticles for Targeted Drug Delivery;2019

4. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma;Veterinary and Comparative Oncology;2018-07-12

5. Advancements in Nanomedicine for Multiple Myeloma;Trends in Molecular Medicine;2018-06